Interaction of Statins and Nondepolarizing Muscle Relaxants

October 22, 2014 updated by: Huang-wei LV
provide evidence for prevention or reduction muscle pain.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The purpose of this study is to determine interaction of statins and nondepolarizing muscle relaxant,In order to provide evidence for prevention or reduction muscle pain.

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Liaoning
      • Shenyang, Liaoning, China, 110001
        • Recruiting
        • China Medical University
        • Contact:
        • Principal Investigator:
          • Huang-wei LV, Professor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months.

Patients not taking simvastatin, lovastatin, atorvastatin, or pravastatin for at least three months

Description

Inclusion Criteria:

  • Patients with American Society of Anesthesiologists physical status I-III
  • Patients taking statins for at least 3 months and those who had never used statins were considered to be eligible

Exclusion Criteria:

  • Orthopedic
  • Spinal surgery
  • Surgery involving extensive muscle manipulation
  • History of liver and kidney failure
  • Neuromuscular disease
  • Susceptibility to or family history of malignant hyperthermia
  • Extensive denervation of skeletal muscle
  • Chronic pain syndromes
  • Taking medications that might interact with the effect of rocuronium or serum myoglobin difficult intubation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Statin use group
patients taking statins for at least 3 months
Drug: Rocuronium
Rocuronium 0.6mg/kg iv single dose
Other Names:
  • Esmeron
  • Rocuronium Bromide Injection
  • http://www.msdchina.com.cn/
non statin use
no history of taking statin
Drug: Rocuronium
Rocuronium 0.6mg/kg iv single dose
Other Names:
  • Esmeron
  • Rocuronium Bromide Injection
  • http://www.msdchina.com.cn/

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
plasma myoglobin concentration
Time Frame: 20 minutes after administration
20 minutes after administration

Secondary Outcome Measures

Outcome Measure
Time Frame
muscle pain
Time Frame: 2 and 24 hours postoperatively
2 and 24 hours postoperatively
serum potassium concentration
Time Frame: 2 and 24 hours postoperatively
2 and 24 hours postoperatively
plasma creatine phosphokinase concentration
Time Frame: 2 and 24 hours postoperatively
2 and 24 hours postoperatively
urine myoglobin and onset plus duration of succinylcholine block
Time Frame: 2 and 24 hours postoperatively
2 and 24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Huang-wei LV

Investigators

  • Study Director: Huangwei Lv, Professor, the Anesthesiology Department

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2014

Primary Completion (Anticipated)

September 1, 2015

Study Completion (Anticipated)

September 1, 2015

Study Registration Dates

First Submitted

August 14, 2014

First Submitted That Met QC Criteria

August 20, 2014

First Posted (Estimate)

August 21, 2014

Study Record Updates

Last Update Posted (Estimate)

October 23, 2014

Last Update Submitted That Met QC Criteria

October 22, 2014

Last Verified

October 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2014071801

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Rocuronium

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe